Orikine Bio
Orikine Bio is a pioneering biotechnology company focused on developing precision-engineered bi-specific cytokine therapies for autoimmune and inflammatory diseases. Founded in 2022 as a spin-off from the Centre for Genomic Regulation in Barcelona, the company leverages its proprietary Foldikine™ platform to reprogram immune responses, aiming to restore proper immune function and treat conditions like rheumatoid arthritis and Crohn's disease. With strong investor support and a rapidly advancing pipeline, Orikine Bio is committed to rewriting the future of medicine through innovative immune system reprogramming therapies.
Industries
Nr. of Employees
small (1-50)
Orikine Bio
Products
Bi‑specific cytokine therapeutic candidate (macrophage reprogramming)
Preclinical biologic candidate that reprograms macrophages to treat Th1‑driven inflammatory diseases; advancing toward IND‑enabling studies.
Additional preclinical programs targeting Th2 and Treg modulation
Early‑stage programs that apply bi‑specific cytokine design to Th2‑driven diseases and regulatory T cell modulation for autoimmune disorders.
Bi‑specific cytokine therapeutic candidate (macrophage reprogramming)
Preclinical biologic candidate that reprograms macrophages to treat Th1‑driven inflammatory diseases; advancing toward IND‑enabling studies.
Additional preclinical programs targeting Th2 and Treg modulation
Early‑stage programs that apply bi‑specific cytokine design to Th2‑driven diseases and regulatory T cell modulation for autoimmune disorders.
Expertise Areas
- Cytokine engineering
- Protein engineering
- Computational protein design
- Immune cell reprogramming
Key Technologies
- Bi‑specific cytokine design
- Computational protein design and modelling
- Immune cell‑targeted biologics
- Stability/half‑life engineering